PMGC Holdings Inc. (ELAB )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ELAB
- Company PMGC Holdings Inc.
- Price $5.99
- Changes Percentage 68.26
- Change 2.43
- Day Low $3.52
- Day High $6.46
- Year High $467.37
- Year Low $1.62
- Market Cap $105,879
- Price Avg 50 EMA (D) $9.4
- Price Avg 200 EMA (D) $103.96
- Exchange NASDAQ
- Volume 42,623,942
- Average Volume 2,867,437
- Open $3.92
- Previous Close $3.56
- EPS -209.46
- PE -0.03
- Earnings Announcement 2026-03-26 04:00:00
- Shares Outstanding $17,676
Company brief: PMGC HOLDINGS INC. (ELAB )
- Healthcare
- Biotechnology
- Dr. Jordan R. Plews Ph.D.
- US
- N/A
- 11-30--0001
- US28622K1043
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
ELAB Corporation News
![PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024](https://images.financialmodelingprep.com/news/pmgc-holdings-inc-nasdaq-elab-reports-2025-annual-results-20260330.jpg)
PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024
globenewswire.com -- Deploys Capital into Cash-Flowing Manufacturing Businesses in Aerospace, Defense and IT Packaging Advances Dual Myostatin Assets Targeting Muscle Preservation in Potential Combination with GLP-1 Treat...